2-(3-fluoro-4-methylphenyl)acetamide | 861393-58-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-fluoro-4-methylphenyl)acetamide
• 英文别名: (3-fluoro-4-methyl-phenyl)-acetamide
• CAS: 861393-58-0
• 化学式: C₉H₁₀FNO
• 分子量: 167.183
• InChiKey: UQTGDJRVQGSLDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  T406石油添加剂 、 特戊醛 、 2-(3-fluoro-4-methylphenyl)acetamide 生成 N-[1-(1H-1,2,3-benzotriazol-1-yl)-2,2-dimethylpropyl]-2-(3-fluoro-4-methylphenyl)acetamide
  参考文献：
  名称：

  P2X7 antagonists for treating neuropathic pain

  摘要：

  本发明揭示了一种使用式I化合物或含有式I化合物的组合物治疗神经病性疼痛的方法。

  公开号：

  US20050171195A1
• 作为产物：
  描述：

  2-(3-fluoro-4-methylphenyl)acetyl chloride 在 氨 作用下， 以 四氢呋喃 为溶剂， 反应 0.33h， 以4.6 g的产率得到2-(3-fluoro-4-methylphenyl)acetamide
  参考文献：
  名称：

  Discovery and Biological Evaluation of Novel Cyanoguanidine P2X₇ Antagonists with Analgesic Activity in a Rat Model of Neuropathic Pain

  摘要：

  We disclose the design of a novel series of cyanoguanidines that are potent (IC50 similar or equal to 10-100 nM) and selective (>= 100-fold) P2X(7) receptor antagonists against the other P2 receptor subtypes such as the P2Y(2), P2X(4), and P2X(3). We also found that these P2X(7) antagonists effectively reduced nociception in a rat model of neuropathic pain (Chung model). Particularly, analogue 53 proved to be effective in the Chung model, with an ED50 of 38 mu mol/kg after intraperitoneal administration. In addition compound 53 exhibited antiallodynic effects following oral administration and maintained its efficacy following repeated administration in the Chung model. These results suggest an important role of P2X(7) receptors in neuropathic pain and therefore a potential use of P2X(7) antagonists as novel therapeutic tools for the treatment of this type of pain.

  DOI：

  10.1021/jm8015848

文献信息

• Sulfonamide-based compounds as protein tyrosine kinase inhibitors
  申请人：Thrash Thomas

  公开号：US20060004197A1

  公开（公告）日：2006-01-05

  Various sulfonamide-based compounds are able to selectively inhibit the Src family of tyrosine kinases. These compounds are useful in the treatment of various diseases including hyperproliferative diseases, hematologic diseases, osteoporosis, neurological diseases, autoimmune diseases, allergic/immunological diseases, or viral infections.

  各种基于磺胺的化合物能够选择性地抑制Src家族的酪氨酸激酶。这些化合物在治疗各种疾病中很有用，包括高增殖性疾病、血液学疾病、骨质疏松症、神经系统疾病、自身免疫疾病、过敏/免疫疾病或病毒感染。
• P2X7 antagonists for treating neuropathic pain
  申请人：Carroll A. William

  公开号：US20050171195A1

  公开（公告）日：2005-08-04

  The present invention discloses a method for treating neuropathic pain using compounds of formula I or compositions containing compounds of formula I.

  本发明公开了一种利用式I化合物或含有式I化合物的组合物治疗神经病性疼痛的方法。
• METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP3633380A1

  公开（公告）日：2020-04-08

  A method for predicting a therapeutic effect of a chemotherapy using an antitumor agent comprising an LSD1 inhibitor in a cancer patient based on an expression level of INSM1 in a sample containing tumor cells isolated from the cancer patient.

  一种根据从癌症患者体内分离出的含有肿瘤细胞的样本中 INSM1 的表达水平，预测使用包含 LSD1 抑制剂的抗肿瘤药物的化疗对癌症患者的治疗效果的方法。
• Biphenyl compound or salt thereof
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US10723742B2

  公开（公告）日：2020-07-28

  A compound or a salt thereof represented by Formula (I). An LSD1 inhibitor containing the compound or a salt thereof as an active ingredient. A pharmaceutical composition containing the compound or salt thereof. An antitumor agent containing the compound or a salt thereof as an active ingredient.

  由式（I）代表的化合物或其盐。以该化合物或其盐为活性成分的 LSD1 抑制剂。含有该化合物或其盐的药物组合物。一种含有该化合物或其盐作为活性成分的抗肿瘤剂。
• ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US20210177826A1

  公开（公告）日：2021-06-17

  An antitumor formulation comprising a biphenyl compound having LSD1 inhibitory activity or a salt thereof and one or more other antitumor agents that are administered in combination, the compound being represented by Formula (I): wherein ring A, ring B, R1 to R6, l, m, and n are as defined in the specification.